Hyperthermic intraperitoneal chemotherapy
DOI:
https://doi.org/10.6016/ZdravVestn.2836Keywords:
hyperthermic intraperitoneal chemotherapy, cytoreductive surgery, colorectal cancer, peritoneal carcinosis, metastasesAbstract
In the past, patients with peritoneal metastases have been treated only with palliative therapy. Their state was deemed to be incurable. The median survival time was approximately two months. The therapeutic approach started to change in the nineties. Some researchers were of the opinion that peritoneal metastases were, in certain cases, only a locoregional disease and consequently, the patient could not only be treated, but cured. One of the main supporters of this theory and new treatment approach was Paul Sugarbaker. The proposed treatment consisted of cytoreductive surgery in combination with intraperitoneal chemotherapy. The purpose of the surgical procedure is macroscopic elimination of the tumour and removal of its microscopic remains via intraperitoneal chemotherapy. The procedure in which we apply a heated chemotherapeutic agent is known as hyperthermic intraperitoneal chemotherapy. Heat on its own has some direct anti-tumour effects. It causes protein denaturation, lysosomal activation and increased apoptotic cell death. If the chemotherapeutic agent is heated, complex chemical reactions take place, which promote its effectiveness and increase the depth of penetration. The best results achieved by this method have been reported in colorectal carcinoma, appendiceal malignancies, ovarian carcinoma and peritoneal mesothelioma. In the paper, the authors present this complex procedure, indications, criteria of patient selection and contemporary knowledge on the effectiveness of this method of treatment for certain types of cancer.
Downloads
References
1. DeVita VT, Lawrence TS, Rosenberg SA. Peritoneal Metastases and Peritoneal Mesothelioma. In: Deraco M, Elias DM, Glehen O, Helm CW, Sugarbaker PH, Verwaal VJ. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 10th ed. Philadelphia: Wolters Kluwer Health Adis; 2015. p. 2234. Available from: https://www.lww.co.uk/devita-hellman-and-rosenbergs-cancer-principles-practice-of-oncology-10-edition.
2. Lambert LA, Harris A. Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: current clinical practice or misnomer? J Gastrointest Oncol. 2016;7(1):112-21.
PMID: 26941989
DOI: 10.3978/j.issn.2078-6891.2015.132
3. Canbay E, Yonemura Y, Brucher B, Baik SH, Sugarbaker PH. Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases. Chin J Cancer Res. 2014;26(1):1-3.
DOI: 10.3978/j.issn.1000-9604.2014.02.06
PMID: 24653620
4. Dehal A, Smith JJ, Nash GM. Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. J Gastrointest Oncol. 2016;7(1):143-57.
DOI: 10.3978/j.issn.2078-6891.2015.112
PMID: 26941992
5. Arjona-Sánchez A, Medina-Fernández FJ, Muñoz-Casares FC, Casado-Adam A, Sánchez-Hidalgo JM, Rufián-Peña S. Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview. World J Gastrointest Oncol. 2014;6(10):407-12.
DOI: 10.4251/wjgo.v6.i10.407
PMID: 25320657
6. Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC—overview and basics. Cancer Invest. 2012;30(3):209-24.
DOI: 10.3109/07357907.2012.654871
PMID: 22360361
7. Poskus E, Strupas K, Gushchin V, Sugarbaker PH. Cytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live Surgery. Viszeralmedizin. 2014;30(5):353-9.
DOI: 10.1159/000368685
PMID: 26535046
8. Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016;7(1):29-44.
PMID: 26941982
DOI: 10.3978/j.issn.2078-6891.2015.105
9. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003;22(4):465-72.
DOI: 10.1023/A:1023791229361
PMID: 12884919
10. Dubé P, Sideris L, Law C, Mack L, Haase E, Giacomantonio C, et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol. 2015;22(2):e100-12.
DOI: 10.3747/co.22.2058
PMID: 25908915
11. Bhatt A, Goéré D. Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian J Surg Oncol. 2016;7(2):177-87.
DOI: 10.1007/s13193-016-0499-z
PMID: 27065708
12. Seshadri RA, Glehen O. The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer. Indian J Surg Oncol. 2016;7(2):198-207.
DOI: 10.1007/s13193-016-0502-8
PMID: 27065710
13. Hayes-Jordan A, Green H, Prieto V, Wolff JE. Unusual cases: melanomatosis and nephroblastomatosis treated with hyperthermic intraperitoneal chemotherapy. J Pediatr Surg. 2012;47(4):782-7.
DOI: 10.1016/j.jpedsurg.2011.12.018
PMID: 22498396
14. Cardi M, Sammartino P, Framarino ML, Biacchi D, Cortesi E, Sibio S, et al. Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: a preliminary report on 5 cases. Breast. 2013;22(5):845-9.
DOI: 10.1016/j.breast.2013.02.020
PMID: 23523180
15. Honore C, Goere D, Dartigues P, Burtin P, Dumont F, Elias D. Peritoneal carcinomatosis from solid pseudopapillary neoplasm (Frantz’s tumour) of the pancreas treated with HIPEC. Anticancer Res. 2012;32(3):1069-73.
PMID: 22399634
16. Salti GI, Ailabouni L, Undevia S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis. Ann Surg Oncol. 2012;19(5):1410-5.
DOI: 10.1245/s10434-012-2240-7
PMID: 22302269
17. Randle RW, Swett KR, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. Am Surg. 2013;79(6):620-4.
PMID: 23711273
18. Beeharry MK, Liu WT, Yao XX, Yan M, Zhu ZG. A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement. Transl Gastroenterol Hepatol. 2016;1:77.
DOI: 10.21037/tgh.2016.08.05
PMID: 28138643
19. Sugarbaker H. Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. In: Sugarbaker H. Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Woodbury: Cine-Med Publishing; 2012. pp. 57-78.
20. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al.; French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608-18.
DOI: 10.1002/cncr.25356
PMID: 20737573
21. Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 2014;50(2):332-40.
DOI: 10.1016/j.ejca.2013.09.024
PMID: 24157254
22. Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol. 2016;7(1):99-111.
PMID: 26941988
23. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29-42.
DOI: 10.1097/00000658-199501000-00004
PMID: 7826158
24. Ceelen WP, Påhlman L, Mahteme H. Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res. 2007;134:195-214.
PMID: 17633055
25. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12(3):689-701.
DOI: 10.1016/S1055-3207(03)00029-2
PMID: 14567025
26. Benoit L, Cheynel N, Ortega-Deballon P, Giacomo G, Chauffert B, Rat P. Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs. Ann Surg Oncol. 2008;15(2):542-6.
DOI: 10.1245/s10434-007-9635-x
27. Lemoine L, Sugarbaker P, Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum. World J Gastroenterol. 2016;22(34):7692-707.
DOI: 10.3748/wjg.v22.i34.7692
PMID: 27678351
28. Bhatt A, Glehen O. The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review. Indian J Surg Oncol. 2016;7(2):188-97.
DOI: 10.1007/s13193-016-0501-9
PMID: 27065709
29. Gilly FN, Cotte E, Brigand C, Monneuse O, Beaujard AC, Freyer G, et al. Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol. 2006;32(6):597-601.
DOI: 10.1016/j.ejso.2006.03.002
PMID: 16617003
30. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3.
DOI: 10.1186/1477-7800-2-3
PMID: 15701175
31. Sugarbaker PH. Colorectal cancer: prevention and management of metastatic disease. BioMed Res Int. 2014;2014:782890.
DOI: 10.1155/2014/782890
PMID: 24783222
32. Sammartino P, Sibio S, Biacchi D, Cardi M, Accarpio F, Mingazzini P, et al. Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC. Gastroenterol Res Pract. 2012;2012:141585.
DOI: 10.1155/2012/141585
PMID: 22645605
33. Lungoci C, Mironiuc AI, Muntean V, Oniu T, Leebmann H, Mayr M, et al. Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol. 2016;8(1):67-82.
DOI: 10.4251/wjgo.v8.i1.67
PMID: 26798438
34. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196-201.
DOI: 10.1016/j.ejso.2007.04.002
PMID: 17524597
35. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945-9.
DOI: 10.1093/annonc/mdl499
PMID: 17298959
36. Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. J Surg Oncol. 2009;100(4):331-4.
DOI: 10.1002/jso.21321
PMID: 19697441
37. Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol. 2012;19(5):1379-85.
DOI: 10.1245/s10434-012-2238-1
PMID: 22302267
38. Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. Pseudomyxoma peritonei syndrome. Adv Surg. 1996;30:233-80.
PMID: 8960339
39. Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P. Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei. Br J Surg. 2005;92(2):153-8.
DOI: 10.1002/bjs.4862
PMID: 15685704
40. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449-56.
DOI: 10.1200/JCO.2011.39.7166
PMID: 22614976
41. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-403.
DOI: 10.1016/j.ejca.2012.12.027
PMID: 23485231
42. Klaver CE, Musters GD, Bemelman WA, Punt CJ, Verwaal VJ, Dijkgraaf MG, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15(1):428.
DOI: 10.1186/s12885-015-1430-7
PMID: 26003804
43. Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. 2016;13(1):120-35.
DOI: 10.28092/j.issn.2095-3941.2015.0103
PMID: 27144067
44. März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep. 2015;3(4):298-302.
DOI: 10.1093/gastro/gov044
PMID: 26424828
45. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737-43.
DOI: 10.1200/JCO.2003.04.187
PMID: 14551293
46. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426-32.
DOI: 10.1245/s10434-008-9966-2
PMID: 18521686
47. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63-8.
DOI: 10.1200/JCO.2009.23.9285
PMID: 19917863
48. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284-92.
DOI: 10.1200/JCO.2004.10.012
PMID: 15310771
49. Park DG. Is Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy a Safe and Effective Procedure for Treating Patients With a Peritoneal Surface Malignancy? Ann Coloproctol. 2017;33(1):3-4.
DOI: 10.3393/ac.2017.33.1.3
PMID: 28289655
50. Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016;22(3):1114-30.
DOI: 10.3748/wjg.v22.i3.1114
PMID: 26811651
51. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al.; Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370-7.
DOI: 10.1245/s10434-010-1039-7
PMID: 20336386
52. Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275-84.
DOI: 10.1002/jso.23633
PMID: 25042700
53. Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2(2):85-97.
DOI: 10.4251/wjgo.v2.i2.85
PMID: 21160926
54. Doubeni CA, Doubeni AR, Myers AE. Diagnosis and Management of Ovarian Cancer. Am Fam Physician. 2016;93(11):937-44.
PMID: 27281838
55. Spiliotis J, Halkia E, de Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol. 2016;23(3):e266-75.
DOI: 10.3747/co.23.2831
PMID: 27330364
56. Shetty SJ, Bathla L, Govindarajan V, Thomas P, Loggie BW. Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg. 2014;80(4):348-52.
PMID: 24887664
57. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42.
DOI: 10.1200/JCO.2009.23.9640
PMID: 19917862
58. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, et al.; Peritoneal Surface Oncology Group. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011;117(9):1855-63.
DOI: 10.1002/cncr.25640
PMID: 21509762
59. Cotte E, Passot G, Gilly FN, Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010;2(1):31-5.
DOI: 10.4251/wjgo.v2.i1.31
PMID: 21160814
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
